EuroMed Therapeutics is building the ninth Israeli licensed producer to capitalize on the domestic medical marijuana market and Europe’s nascent export market — worth upwards of $66 billion .

- Israeli Licensed Producer: EuroMed is building Israel’s ninth licensed producer, compared to more than 160 LPs across Canada.

- Low Cost Production: Israel has an ideal climate for year round outdoor cannabis production — significantly lowering costs.

- European End Markets: Israel’s strategic location makes it ideal for exporting to Europe, where consumers pay $18+ per gram.

- Access to Talent: Israel is a global leader in cannabis research, as well as a biotech and pharmaceutical hub.

https://euromedtherapeutics.com/

$$$$UNVC$$$$